ISDA

Deposition Date 2021-12-14

Release Date 2022-03-02

Last Version Date 2024-02-28

Entry Detail

PDB ID:

7T79

Keywords:

TRANSFERASE

Title:

CRYSTAL STRUCTURE OF GLUCOKINASE (HEXOKINASE 4) COMPLEXED WITH LIGAND AKA DIETHYL {[3-(3-{[5-(AZETIDINE-1-CARBON YL)PYRAZIN-2-YL]OXY}-5-(PROPAN-2-YLOXY)BENZAMIDO)-1H- PYRAZOL-1-YL]METHYL}PHOSPHONATE

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.40 Å

R-Value Free:

0.25

R-Value Work:

0.21

R-Value Observed:

0.21

Space Group:

P 21 21 21

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Isoform 2 of Hexokinase-4
Gene (Uniprot):GCK
Chain IDs:A, B
Chain Length:466
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P35557 Pfam ID:PF00349, PF03727 EC:2.7.1.1

Ligand Molecules

G1S

GLC

Primary Citation

Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1 H -pyrazol-1-yl)methyl)phosphonate (BMS-820132).

Shi, Y, Wang, Y, Meng, W, Brigance, R.P, Ryono, D.E, Bolton, S, Zhang, H, Chen, S, Smirk, R, Tao, S, Tino, J.A, Williams, K.N, Sulsky, R, Nielsen, L, Ellsworth, B, Wong, M.K.Y, Sun, J.H, Leith, L.W, Sun, D, Wu, D.R, Gupta, A, Rampulla, R, Mathur, A, Chen, B.C, Wang, A, Fuentes-Catanio, H.G, Kunselman, L, Cap, M, Zalaznick, J, Ma, X, Liu, H, Taylor, J.R, Zebo, R, Jones, B, Kalinowski, S, Swartz, J, Staal, A, O'Malley, K, Kopcho, L, Muckelbauer, J.K, Krystek Jr, S.R, Spronk, S.A, Marcinkeviciene, J, Everlof, G, Chen, X.Q, Xu, C, Li, Y.X, Langish, R.A, Yang, Y, Wang, Q, Behnia, K, Fura, A, Janovitz, E.B, Pannacciulli, N, Griffen, S, Zinker, B.A, Krupinski, J, Kirby, M, Whaley, J, Zahler, R, Barrish, J.C, Robl, J.A, Cheng, P.T.W.Show

J.Med.Chem. 65 4291 4317 (2022)

PMID: 35179904 DOI: 10.1021/acs.jmedchem.1c02110

Abstact

Glucokinase (GK) is a key regulator of glucose homeostasis, and its small-molecule activators represent a promising opportunity for the treatment of type 2 diabetes. Several GK activators have been advanced into clinical trials and have demonstrated promising efficacy; however, hypoglycemia represents a key risk for this mechanism. In an effort to mitigate this hypoglycemia risk while maintaining the efficacy of the GK mechanism, we have investigated a series of amino heteroaryl phosphonate benzamides as ''partial" GK activators. The structure-activity relationship studies starting from a "full GK activator" 11, which culminated in the discovery of the "partial GK activator" 31 (BMS-820132), are discussed. The synthesis and in vitro and in vivo preclinical pharmacology profiles of 31 and its pharmacokinetics (PK) are described. Based on its promising in vivo efficacy and preclinical ADME and safety profiles, 31 was advanced into human clinical trials.

Legend

Protein

Chemical

Disease

Primary Citation of related structures